Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective study analysing use of dolutegravir (DTG) + lamivudine (3TC) in ART-naive and pre-treated people living with HIV in URBAN cohort study

Next Previous
X
Search
Trial Profile

A prospective study analysing use of dolutegravir (DTG) + lamivudine (3TC) in ART-naive and pre-treated people living with HIV in URBAN cohort study

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Dec 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dolutegravir/lamivudine (Primary)
  • Indications HIV infections
  • Focus Therapeutic Use
  • Acronyms URBAN

    • Most Recent Events

    • 26 Oct 2022 Results ( At data-cut, n=352 ) assessing effectiveness, tolerability, metabolic parameters and patient-reported outcomes in people living with HIV using DTG+3TC,presented at the 16th International Congress on Drug Therapy and HIV Infection
    • 30 Oct 2021 Results at 12-months were presented at the 18th European AIDS Conference.
    • 12 Nov 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top